FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2537947276> ?p ?o ?g. }

• W2537947276 abstract "Abstract Background Effective anti-myeloma combination therapies including carfilzomib and lenaldiomide (Ln) induce deep clinical responses and durable remissions. Attainment of stringent (s)- complete response (CR), as well as negative minimal residual disease (MRD) by sensitive molecular techniques and multiparameter flowcytometry (MFC) in bone marrow is predictive of improved outcome. Here we report the association of HLC, FLC, and other prognostic factors to predict early CR and MRD in our ongoing prospective clinical CRd trials for multiple myeloma (MM) and high risk smoldering MM (SMM) patients. Methods Treatment consisted of 8 cycles of CRd combination, followed by 24 cycles of Ln maintenance; the treatment schedule for SMM and MM was the same. Serum FLC, and immunoglobulin HLC pairs were determined using the Freelite and Hevylite assay (Binding Site, Birmingham, UK). The clonal FLC and HLC burden was measured as the difference between involved and uninvolved FLC (FLC-diff) and involved and uninvolved HLC pair (HLC-diff), as well as FLC κ to λ ratio (FLC ratio; normal range 0.26 to 1.65), and HLC ratios IgGκ/IgGλ and IgAκ/IgAλ; normal ranges, 1.12 to 3.21 and 0.78 to 1.94, respectively. Patients were evaluated for clinical responses by standard criteria and for MRD by sensitive MFC. Patients with any type of CR (CR, near(n)CR or sCR) were divided into groups according to whether their best response occurred in cycles 1-4, 5-8 or 9+, or 1-4 vs. 5+. Dichotomous parameters were compared using Fisher’s exact test. The associations between cycle categories and dichotomous parameters were determined using a Cochran-Armitage test. Continuous parameters were compared between two groups using an exact Wilcoxon rank sum test, while continuous categories were compared across cycle categories using a Jonckheere-Terpstra test for trend. Logistic regression analysis was used to predict if any type of CR would occur within 1-4 cycles. All p-values are two-tailed and reported without formal adjustment for multiple comparisons. Results We included 38 MM and 12 SMM patients (27 male, 23 female; median age 59.5; range 40–88). Among these patients, median M-spike was 2.5g/dL, median FLC-diff was 28.94mg/dL (range -0.06–1619.87); isotypes included 37–IgG, 7–IgA, 5–κ, and 1–λ; immunoparesis was present in 46 (92%); and abnormal FLC ratio in 47 (94%). Six patients with light chain only disease were excluded from HLC analyses; among 43 analyzed, all had abnormal HLC ratio, and median HLC-diff was 22.14 g/L (range 1.85–109.13). Of 8 patients, in whom M spike could not be precisely evaluated due to migration in beta region, accurate HLC pair analysis was possible in 7. A total of 33 patients achieved CR: 22–sCR, 3–CR, and 8–nCR (66%). The number of CRd cycles administered to first CR of any type was 1-4 in 15 patients, 5-8 in 12, and 9-17 in 6; median number of cycles was 6. Among patients who achieved CR, 23 CR/sCR + 4 nCR patients underwent MRD assessment, and all were negative. There was a strong trend of an association between a normalized FLC ratio after 1 cycle of CRd and all types of CR (p= 0.003) obtained in first 4 cycles. Similarly normalization of the HLC ratio after 2 cycles of CRd was significantly associated with obtaining a nCR/CR/sCR (p=0.0098) or sCR (p=0.001) in 1-4 cycles; CR was reached in 1-4 cycles in 7/9 (78%) patients who normalized their HLC ratios after 2 cycles, as compared with 4/15 (27%) among those who did not. In a univariate analysis, FLC-diff after 1 cycle of CRd (p=0.0035), and HLC-diff after 2 cycles of CRd (p=0.0092) was associated with a significant trend to achieving nCR/CR/sCR in 1-4 vs.5-8 vs.9+ cycles. In a multivariate model that initially included M spike, FLC-diff, normalized FLC ratio, HLC-diff, as well as normalized HLC ratio, only HLC-diff after 2 cycles of CRd (<2.6 g/L vs. ≥ 2.6 g/L) remained as an independent factor predictive of response. In this model, 90.9% (10/11) of those whose best response occurred in cycles 1-4, as well as 76.9% (10/13) of those whose best response occurred in cycles 5+ could be predicted by HLC-diff after 2 cycles of CRd. Conclusions Early monitoring (after 2 cycles) of HLC patterns is an independent predictor of rapid response among high risk SMM and newly diagnosed MM patients treated with CRd therapy. Biomarkers predictive of rapid responses to therapy have a major clinical potential as they will allow better tailoring of treatment with the goal to maximize survival and minimize toxicities. Disclosures: Off Label Use: Treatment of smoldering multiple myeloma- carfilzomib and lenalidomide." @default.
• W2537947276 created "2016-10-28" @default.
• W2537947276 creator A5010930696 @default.
• W2537947276 creator A5014636271 @default.
• W2537947276 creator A5016656825 @default.
• W2537947276 creator A5017057018 @default.
• W2537947276 creator A5044239219 @default.
• W2537947276 creator A5044366730 @default.
• W2537947276 creator A5044681793 @default.
• W2537947276 creator A5045179755 @default.
• W2537947276 creator A5046553822 @default.
• W2537947276 creator A5046878636 @default.
• W2537947276 creator A5048088566 @default.
• W2537947276 creator A5048966043 @default.
• W2537947276 creator A5060701531 @default.
• W2537947276 creator A5062086023 @default.
• W2537947276 creator A5065696086 @default.
• W2537947276 creator A5067074464 @default.
• W2537947276 creator A5079704265 @default.
• W2537947276 creator A5081837203 @default.
• W2537947276 creator A5082004555 @default.
• W2537947276 creator A5082376289 @default.
• W2537947276 creator A5086510250 @default.
• W2537947276 creator A5089952063 @default.
• W2537947276 date "2013-11-15" @default.
• W2537947276 modified "2023-09-28" @default.
• W2537947276 title "Serum Heavy-Light Chains (HLC) and Free Light Chains (FLC) As Predictors For Early CR In Newly Diagnosed Myeloma Patients Treated With Carfilzomib, Lenalidomide, and Dexamethasone (CRd)" @default.
• W2537947276 doi "https://doi.org/10.1182/blood.v122.21.762.762" @default.
• W2537947276 hasPublicationYear "2013" @default.
• W2537947276 type Work @default.
• W2537947276 sameAs 2537947276 @default.
• W2537947276 citedByCount "3" @default.
• W2537947276 countsByYear W25379472762015 @default.
• W2537947276 countsByYear W25379472762017 @default.
• W2537947276 countsByYear W25379472762018 @default.
• W2537947276 crossrefType "journal-article" @default.
• W2537947276 hasAuthorship W2537947276A5010930696 @default.
• W2537947276 hasAuthorship W2537947276A5014636271 @default.
• W2537947276 hasAuthorship W2537947276A5016656825 @default.
• W2537947276 hasAuthorship W2537947276A5017057018 @default.
• W2537947276 hasAuthorship W2537947276A5044239219 @default.
• W2537947276 hasAuthorship W2537947276A5044366730 @default.
• W2537947276 hasAuthorship W2537947276A5044681793 @default.
• W2537947276 hasAuthorship W2537947276A5045179755 @default.
• W2537947276 hasAuthorship W2537947276A5046553822 @default.
• W2537947276 hasAuthorship W2537947276A5046878636 @default.
• W2537947276 hasAuthorship W2537947276A5048088566 @default.
• W2537947276 hasAuthorship W2537947276A5048966043 @default.
• W2537947276 hasAuthorship W2537947276A5060701531 @default.
• W2537947276 hasAuthorship W2537947276A5062086023 @default.
• W2537947276 hasAuthorship W2537947276A5065696086 @default.
• W2537947276 hasAuthorship W2537947276A5067074464 @default.
• W2537947276 hasAuthorship W2537947276A5079704265 @default.
• W2537947276 hasAuthorship W2537947276A5081837203 @default.
• W2537947276 hasAuthorship W2537947276A5082004555 @default.
• W2537947276 hasAuthorship W2537947276A5082376289 @default.
• W2537947276 hasAuthorship W2537947276A5086510250 @default.
• W2537947276 hasAuthorship W2537947276A5089952063 @default.
• W2537947276 hasConcept C126322002 @default.
• W2537947276 hasConcept C143998085 @default.
• W2537947276 hasConcept C159654299 @default.
• W2537947276 hasConcept C191093355 @default.
• W2537947276 hasConcept C203014093 @default.
• W2537947276 hasConcept C2776063141 @default.
• W2537947276 hasConcept C2776364478 @default.
• W2537947276 hasConcept C2779823535 @default.
• W2537947276 hasConcept C2780007613 @default.
• W2537947276 hasConcept C2780108899 @default.
• W2537947276 hasConcept C2780401358 @default.
• W2537947276 hasConcept C71924100 @default.
• W2537947276 hasConcept C90924648 @default.
• W2537947276 hasConceptScore W2537947276C126322002 @default.
• W2537947276 hasConceptScore W2537947276C143998085 @default.
• W2537947276 hasConceptScore W2537947276C159654299 @default.
• W2537947276 hasConceptScore W2537947276C191093355 @default.
• W2537947276 hasConceptScore W2537947276C203014093 @default.
• W2537947276 hasConceptScore W2537947276C2776063141 @default.
• W2537947276 hasConceptScore W2537947276C2776364478 @default.
• W2537947276 hasConceptScore W2537947276C2779823535 @default.
• W2537947276 hasConceptScore W2537947276C2780007613 @default.
• W2537947276 hasConceptScore W2537947276C2780108899 @default.
• W2537947276 hasConceptScore W2537947276C2780401358 @default.
• W2537947276 hasConceptScore W2537947276C71924100 @default.
• W2537947276 hasConceptScore W2537947276C90924648 @default.
• W2537947276 hasLocation W25379472761 @default.
• W2537947276 hasOpenAccess W2537947276 @default.
• W2537947276 hasPrimaryLocation W25379472761 @default.
• W2537947276 hasRelatedWork W2240448657 @default.
• W2537947276 hasRelatedWork W2328967846 @default.
• W2537947276 hasRelatedWork W2418160128 @default.
• W2537947276 hasRelatedWork W2430823251 @default.
• W2537947276 hasRelatedWork W2513769040 @default.
• W2537947276 hasRelatedWork W2515344960 @default.
• W2537947276 hasRelatedWork W2531238427 @default.
• W2537947276 hasRelatedWork W2732569183 @default.
• W2537947276 hasRelatedWork W2754100254 @default.
• W2537947276 hasRelatedWork W3096295699 @default.
• W2537947276 hasRelatedWork W3199548858 @default.
• W2537947276 isParatext "false" @default.
• W2537947276 isRetracted "false" @default.

• next